2020
Cannabinoids
De Aquino J, Arnaout B. Cannabinoids. 2020, 153-167. DOI: 10.1007/978-3-030-33404-8_10.Peer-Reviewed Original ResearchCannabis use disorderUse of cannabinoidsPotential pharmacokinetic interactionsEffects of cannabinoidsDose-dependent effectPharmacokinetic interactionsPsychotropic medicationsRisk factorsPsychosocial treatmentsPsychiatric disordersUse disordersAddiction specialistsHealthcare providersPsychomotor functioningCannabinoidsSynthetic cannabinoidsDisordersMedicinal useMedicationsPatientsProgressionBrief Training on Medication-Assisted Treatment Improves Community Mental Health Clinicians’ Confidence and Readiness to Address Substance Use Disorders
Iheanacho T, Bommersbach T, Fuehrlein B, Arnaout B, Dike C. Brief Training on Medication-Assisted Treatment Improves Community Mental Health Clinicians’ Confidence and Readiness to Address Substance Use Disorders. Community Mental Health Journal 2020, 56: 1429-1435. PMID: 32062717, PMCID: PMC7429311, DOI: 10.1007/s10597-020-00586-8.Peer-Reviewed Original ResearchConceptsSubstance use disordersMedication-assisted treatmentCommunity mental health cliniciansMental health cliniciansHealth cliniciansPost-training questionnairesUse disordersDisease modelsRoutine practiceCliniciansFactor 1Factor 2Brief trainingDisordersSignificant changesQuestionnaireLimited awarenessTreatmentPublic sector settingsAddictionPreMedicationsPatientsLow confidenceDisease
2017
Effective Switch From Clozapine to Aripiprazole in Treatment-Resistant Schizophrenia and Comorbid Alcohol Use Disorder
Feeley RJ, Arnaout B, Yoon G. Effective Switch From Clozapine to Aripiprazole in Treatment-Resistant Schizophrenia and Comorbid Alcohol Use Disorder. Journal Of Clinical Psychopharmacology 2017, 37: 729-730. PMID: 29028689, DOI: 10.1097/jcp.0000000000000794.Peer-Reviewed Original Research
2011
Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence
Ralevski E, O’Brien E, Jane JS, Dwan R, Dean E, Edens E, Arnaout B, Keegan K, Drew S, Petrakis I. Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence. Journal Of Dual Diagnosis 2011, 7: 64-73. PMID: 26954912, DOI: 10.1080/15504263.2011.569440.Peer-Reviewed Original ResearchEfficacy of acamprosateAlcohol dependenceSchizophrenia spectrum disordersMedication treatmentComorbid schizophreniaSignificant group x time interactionGroup x time interactionComorbid alcohol dependenceAlcohol use disorderSymptoms of schizophreniaX time interactionAcamprosate groupComorbid conditionsTreatment trialsAbstinent patientsClinical trialsSpectrum disorderAcamprosateGeneral populationUse disordersPatientsSchizoaffective disorderPositive symptomsSchizophrenic symptomsConsecutive days
2008
Does a History of Alcohol Use Disorder Affect Response to Antidepressant Medication in Patients With Dysthymic Disorder?
Arnaout B, Batchelder S, Rosenthal R, Hyler S, Hellerstein D. Does a History of Alcohol Use Disorder Affect Response to Antidepressant Medication in Patients With Dysthymic Disorder? Journal Of Dual Diagnosis 2008, 4: 377-393. DOI: 10.1080/15504260802086842.Peer-Reviewed Original ResearchLifetime alcohol use disorderAlcohol use disorderDysthymic disorderUse disordersBaseline Hamilton Depression Rating ScaleHamilton Depression Rating ScaleRating ScaleWeeks of treatmentWeeks of pharmacotherapyDepression Rating ScaleHDRS-24Medication trialsAlcoholic patientsAdult outpatientsRate of responseLifetime historySecondary analysisDisordersGreater decreaseRemissionPharmacotherapyPatientsAdequate evaluationTreatmentPreliminary findingsDiagnosing co-morbid drug use in patients with alcohol use disorders.
Arnaout B, Petrakis IL. Diagnosing co-morbid drug use in patients with alcohol use disorders. Alcohol Research 2008, 31: 148-54. PMID: 23584816, PMCID: PMC3860455.Peer-Reviewed Original Research